| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.3 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.05 | 0.4 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.4 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.061 | 0.4 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.051 | 0.4 |